Sodium–glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a fundamental therapy for patients with heart failure with preserved ejection fraction (HFpEF), a population that has historically lacked effective treatment options. Large randomized controlled trials, such as EMPEROR-Preserved [1] and DELIVER [2], have demonstrated that SGLT2i significantly reduce the composite of cardiovascular (CV) death and hospitalization for heart failure (HFH) in this population, irrespective of diabetes status.
